Geotherapeutics of primary biliary cirrhosis: Bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom

Hepatology

Volumn 46, Issue 4, 2007, Pages 963-965

  Corpechot, Christophe ^a   Poupon, Raoul ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

URSODEOXYCHOLIC ACID;

CANCER RISK; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EDITORIAL; HUMAN; LIVER CANCER; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; UNITED KINGDOM;

CHOLAGOGUES AND CHOLERETICS; FRANCE; GREAT BRITAIN; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS; LIVER TRANSPLANTATION; RISK FACTORS; URSODEOXYCHOLIC ACID;

EID: 36348946992     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21871     Document Type: Editorial

References (25)

1. Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. HEPATOLOGY 2007;46. DOI: 10.1002/hep.21795.
2. Walley T, Mantgani A. The UK general practice research database. Lancet 1997;350:1097-1099.
3. Prince MI, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123:1044-1051.
4. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261-1273.
5. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.
6. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354:1053-1060.
7. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002;No. 1:CD000551.
8. Lindor KD, Poupon R, Heathcote EJ, Therneau T. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000;355:657-658.
9. Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101:1529-1538.
10. Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007;102:1-9.
11. Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smidi C, DeSotel CK, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30:830-835.
12. Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39:12-16.
13. Poupon RE, Bonnand AM, Chretien Y, Poupon R, and the UDCA-PBC Study Group. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. HEPATOLOGY 1999;29:1668-1671.
14. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303.
15. Koulentaki M, Moscandrea J, Dimoulios P, Chatzicostas C, Kouroumalis EA. Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment. Dig Dis Sci 2004;49:1190-1195.
16. Chan CW, Gunsar F, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther 2005;21:217-226.
17. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006;101:2044-2050.
18. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130:715-720.
19. Corpechot C, Chretien Y, Chazouilleres O, Poupon R. Biochemical response to UDCA and long-term risk of death or liver transplantation in PBC. J Hepatol 2007;46(Suppl 1):S49.
20. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. HEPATOLOGY 2001;33:22-27.
21. James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV. Primary biliary cirrhosis once rare, now common in the United Kingdom? HEPATOLOGY 1999;30:390-394.
22. Lee J, Belanger A, Friedman S, Bach N. Transplantation trends among primary biliary cirrhosis patients from 1995 to 2004 [Abstract]. HEPATOLOGY 2006;44(Suppl):A628.
23. Agence de la Biomédecine. Rapport Annuel des Activités de Prélèvements et de Greffes Hépatiques en France. 2005. Available at: www.agence-biomedecine.fr.
24. Lindor KD, for the Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997;336:691-695.
25. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcranrz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472.